Eltrombopag Olamine
Brand name: Promacta
Rank #121 of 500 drugs by total cost
$142.8M
Total Cost
10,876
Total Claims
$142.8M
Total Cost
606
Prescribers
$13K
Cost per Claim
50
Beneficiaries
11,101
30-Day Fills
$236K
Avg Cost/Provider
18
Avg Claims/Provider
About Eltrombopag Olamine
Eltrombopag Olamine (sold as Promacta) was prescribed 10,876 times by 606 Medicare Part D providers in 2023, costing the program $142.8M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 118 | Lisinopril (Lisinopril) | $145.8M | 15,744,768 |
| 119 | Ofatumumab (Kesimpta Pen) | $144.6M | 14,774 |
| 120 | Emtricitab/Rilpiviri/Tenof Ala (Odefsey) | $144.1M | 37,441 |
| 121 | Eltrombopag Olamine (Promacta) | $142.8M | 10,876 |
| 122 | Alpha-1-Proteinase Inhibitor (Prolastin C) | $137.9M | 12,352 |
| 123 | Dasatinib (Sprycel) | $136.8M | 10,389 |
| 124 | Oxycodone Hcl/Acetaminophen (Oxycodone-Acetaminophen) | $136.4M | 3,487,099 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology